Intervention

docetaxel

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 317 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials317
Recruiting4
Common conditions25
Lead sponsors shown15
Advertisement

Clinical trials

60 shown
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerNCT06891833 · 2025-06-05
RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 · 2025-05-06
RECRUITING
ctDNA in HER2+ EBC Neoadjuvant TreatmentNCT07335081 · 2024-02-01
RECRUITING
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast CancerNCT05430399 · 2022-06-21
RECRUITING
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.NCT07730151 · 2026-08-01
NOT_YET_RECRUITING
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）NCT07609251 · 2026-05-01
NOT_YET_RECRUITING
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung CancerNCT06319313 · 2024-05-01
NOT_YET_RECRUITING
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerNCT06012435 · 2024-02-21
ACTIVE_NOT_RECRUITING
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerNCT05848011 · 2023-09-28
COMPLETED
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.NCT05834348 · 2023-06-23
COMPLETED
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007 · 2023-02-13
COMPLETED
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerNCT05132075 · 2022-06-15
ACTIVE_NOT_RECRUITING
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung CancerNCT05062980 · 2022-03-30
TERMINATED
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT05348577 · 2022-03-25
ACTIVE_NOT_RECRUITING
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world StudyNCT05287308 · 2022-03-01
NOT_YET_RECRUITING
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)NCT05173987 · 2022-02-03
ACTIVE_NOT_RECRUITING
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLCNCT05106335 · 2022-01-06
TERMINATED
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyNCT04151563 · 2021-04-15
WITHDRAWN
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.NCT04385563 · 2018-11-11
UNKNOWN
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerNCT03338790 · 2017-12-19
COMPLETED
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in SwedenNCT03328364 · 2017-12-01
COMPLETED
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyNCT03933449 · 2016-12-29
COMPLETED
Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast CancerNCT03084237 · 2016-11-01
COMPLETED
A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung CancerNCT02787473 · 2016-10-01
UNKNOWN
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA SignatureNCT02641847 · 2016-01-01
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)NCT02564263 · 2015-12-01
COMPLETED
Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIBNCT02326285 · 2015-11-01
TERMINATED
A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast CancerNCT03017404 · 2015-05-01
COMPLETED
Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer PatientsNCT02376296 · 2015-02-01
COMPLETED
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)NCT02256436 · 2014-10-22
COMPLETED
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational ResearchNCT02231164 · 2014-10-14
TERMINATED
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerNCT02257619 · 2014-09-24
TERMINATED
Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung CancerNCT02145078 · 2014-06-01
TERMINATED
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung CancerNCT01824901 · 2014-01-15
COMPLETED
Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLCNCT02037997 · 2013-12-01
UNKNOWN
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway SignalingNCT01868022 · 2013-10-09
COMPLETED
Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast CancerNCT01959490 · 2013-09-24
COMPLETED
Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer PatientsNCT01939054 · 2013-09-01
UNKNOWN
Fasting on Newly Diagnosed Breast CancerNCT02379585 · 2013-01-01
TERMINATED
XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast CancerNCT01777945 · 2012-12-01
COMPLETED
Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung caNCT02036359 · 2012-05-01
UNKNOWN
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate CancerNCT01468532 · 2011-10-01
COMPLETED
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung CancerNCT01362296 · 2011-09-01
COMPLETED
Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast CancerNCT01352494 · 2011-05-01
UNKNOWN
A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast CancerNCT00964704 · 2011-03-01
WITHDRAWN
A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)NCT01204697 · 2010-11-01
COMPLETED
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)NCT01120184 · 2010-07-31
COMPLETED
Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)NCT01059188 · 2010-05-03
COMPLETED
Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer PatientsNCT01099436 · 2010-04-01
COMPLETED
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)NCT01083615 · 2010-03-01
TERMINATED
PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast CancerNCT00774241 · 2010-01-01
WITHDRAWN
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow MicrometastasesNCT00949247 · 2009-12-01
COMPLETED
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2NCT01160705 · 2009-11-01
COMPLETED
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerNCT00970684 · 2009-09-01
COMPLETED
Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.NCT00933517 · 2009-09-01
COMPLETED
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer PatientsNCT00879619 · 2009-07-01
TERMINATED
Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast CancerNCT00994968 · 2009-07-01
UNKNOWN
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast CancerNCT00845910 · 2009-05-01
TERMINATED
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerNCT00887536 · 2009-05-01
COMPLETED
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC PatientsNCT00890825 · 2009-04-20
COMPLETED

Common conditions

Breast Cancer110Prostate Cancer72Lung Cancer56Non-small Cell Lung Cancer14Recurrent Non-small Cell Lung Cancer8Stage IV Non-small Cell Lung Cancer8Stage IV Prostate Cancer8Unspecified Adult Solid Tumor, Protocol Specific8Carcinoma, Non-Small-Cell Lung7Recurrent Prostate Cancer7Stage IIIB Non-small Cell Lung Cancer7Adenocarcinoma of the Prostate6Head and Neck Cancer6Squamous Cell Lung Cancer6Bladder Cancer5Breast Neoplasms5Non Small Cell Lung Cancer5Prostatic Neoplasms5Adenocarcinoma of the Lung4Large Cell Lung Cancer4Metastatic Cancer4Ovarian Cancer4Bronchoalveolar Cell Lung Cancer3Hormone-resistant Prostate Cancer3Neutropenia3

Trial status mix

COMPLETED203
TERMINATED48
UNKNOWN40
WITHDRAWN10
ACTIVE_NOT_RECRUITING7
NOT_YET_RECRUITING4
RECRUITING4
SUSPENDED1

Phase mix

PHASE2192
PHASE380
PHASE156
NA8
PHASE42
EARLY_PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.